Shattuck Labs (STTK) Stock Price, News & Analysis

Company Overview

Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company’s research is based on its Agonist Redirected Checkpoint (ARC) platform, which is designed to combine immune-cell activation with checkpoint inhibition in a single therapeutic molecule.

Shattuck’s pipeline has included bifunctional fusion proteins such as SL-172154, an investigational therapy designed to engage CD40 ligand and block PD-L1, and SL-173154, which is designed to target CD27 ligand and PD-L1. These programs have been evaluated in clinical studies involving patients with advanced solid tumors and hematologic malignancies. The company’s drug candidates remain investigational and have not been approved for commercial use.

Founded in 2016, Shattuck Labs is based in Austin, Texas, and has maintained research and development operations in North Carolina. The company’s leadership has included co-founder Taylor Schreiber, M.D., Ph.D., who has served as president and chief executive officer. Shattuck Labs became a publicly traded company on the Nasdaq under the symbol STTK in 2020.

Key Stats

• Today's Range: $5.48 to $5.82
• 50-Day Range: $5.33 to $8.06
• 52-Week Range: $1.72 to $8.33
• Volume: 699,500 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.70
• Consensus Rating: Buy

Shattuck Labs Stock Analysis - MarketRank™

Shattuck Labs scored higher than 63% of companies evaluated by MarketBeat, and ranked 363rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Shattuck Labs has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 3 strong buy ratings, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Shattuck Labs has a consensus price target of $13.70, representing about 137.4% upside from its current price of $5.77.

Amount of Analyst Coverage

Shattuck Labs has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Shattuck Labs are expected to decrease in the coming year, from ($0.45) to ($0.49) per share.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.41% of the float of Shattuck Labs has been sold short.

Short Interest Ratio / Days to Cover

Shattuck Labs has a short interest ratio ("days to cover") of 7.24.

Change versus previous month

Short interest in Shattuck Labs has recently decreased by 4.63%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Shattuck Labs does not currently pay a dividend.

Dividend Growth

Shattuck Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.77

News Sentiment

Shattuck Labs has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Shattuck Labs this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for STTK on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shattuck Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.79% of the stock of Shattuck Labs is held by insiders.

Percentage Held by Institutions

58.74% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:STTK
• CIK: 1680367
• Web: www.shattucklabs.com
• Phone: 512-900-4690
• Fax: N/A
• Employees: 40
• Year Founded: 2016

Price Target and Rating

• Average Price Target for Shattuck Labs: $13.70
• High Price Target: $19.00
• Low Price Target: $7.00
• Potential Upside/Downside: +137.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 91,541,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A